Peptides for ADHD
The peptides people most often research for ADHD, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.
- Peptides listed
- 3
- With human trials
- 0
- FDA approved (any use)
- 1
- SemaxACTH(4-10) analogNo study with an outcome for ADHDPubMed search, 11 Oct 2026Human1Animal0Summarised1PCAC voted 8–5 for 503A (Jul 2026)For ADHDOverview
- TirzepatideGLP-1 / GIP dual agonistNo study with an outcome for ADHDPubMed search, 2 Oct 2026Human1Animal0Summarised0FDA approved (Mounjaro, Zepbound)For ADHDOverview
- SelankTuftsin analogNo study with an outcome for ADHDPubMed search, 11 Oct 2026Human0Animal0Summarised0Not FDA approved · research chemicalOverview
What this list does not show
Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.
Search interest is not evidence
This list follows what people search for and discuss. It says nothing about how well any peptide works.Animal results may not carry over
Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.Approval covers specific uses
An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.Combinations are a separate question
Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.What ADHD is
MedlinePlus calls ADHD a neurodevelopmental disorder that is usually first diagnosed in childhood and often lasts into adulthood.[23]
The same page says the exact cause of ADHD is unknown.[23]
There is no human ADHD trial for any listed peptide
Semax and tirzepatide each have 1 human-only PubMed paper that mentions ADHD, and Selank has none; no randomised ADHD trial exists for any of them in the ledger.
Calculated from source our PubMed count ledger ledger (PubMed title/abstract counts, 2026-10-02); semax human only 1, animal only 0, rct 0; tirzepatide human only 1, animal only 0, rct 0; selank human only 0, animal only 0, rct 0. Formula: Counts copied from each peptide ledger: humanOnly = human studies not also tagged animal, animalOnly = animal studies not tagged human, rct = human randomised trials. They count papers mentioning the topic, not positive results.
The one ADHD-specific paper for these peptides is a hypothesis article. Its author proposes Semax may have therapeutic potential in ADHD, citing disturbed dopamine and BDNF function. It reports no patient data.[24]
Common questions
What are the best peptides for ADHD?
None can be ranked: the only ADHD-related paper for the listed peptides is a hypothesis article with no patient data.[24]
Does Semax help ADHD?
One hypothesis paper proposes that Semax may have therapeutic potential in ADHD, citing disturbed dopamine and BDNF function. It reports no patient data.[24]
Explore nearby goals
Sources
- 1PubMed search: semax[tiab] (208 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 2PubMed search: semax[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 3PubMed search: (selank[tiab] OR semax[tiab]) AND (randomized[tiab] OR patients[tiab] OR clinical[tiab]) (48 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 4PubMed search: tirzepatide[ti] AND (SURMOUNT[tiab] OR SURPASS[tiab]) AND randomized controlled trial[pt] (93 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: tirzepatide[ti] AND (SURPASS-2 OR SURPASS-3 OR SURPASS-4 OR SURPASS-5 OR "versus semaglutide" OR "SURPASS-CVOT" OR dulaglutide) (143 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: tirzepatide[ti] AND (steatohepatitis OR NASH OR "heart failure" OR HFpEF OR "preserved ejection" OR cardiovascular) (410 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: tirzepatide[ti] AND (SURPASS-2 OR SURPASS-3 OR SURPASS-1 OR SURPASS-5 OR "SURPASS J-mono") AND randomized controlled trial[pt] (24 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: tirzepatide[ti] AND (steatohepatitis OR "heart failure" OR "SUMMIT" OR "SYNERGY-NASH" OR "phase 2") AND randomized controlled trial[pt] (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: tirzepatide[tiab] AND (meta-analysis[pt] OR systematic review[pt]) AND (weight OR glycemic OR HbA1c OR obesity) (178 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: tirzepatide[tiab] AND (pharmacokinetic*[tiab] OR half-life[tiab]) AND humans[mh] (49 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: tirzepatide[ti] AND (insulin degludec OR "SURPASS-3") AND "type 2 diabetes"[ti] AND randomized controlled trial[pt] (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: tirzepatide[ti] AND (cardiovascular outcomes OR "SURPASS-CVOT" OR "major adverse") (228 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: tirzepatide[tiab] AND (depression OR anxiety OR ADHD OR osteoporosis OR "bone mineral" OR menopause OR "rheumatoid" OR arthritis OR testosterone) (121 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: tirzepatide[tiab] AND ("body composition"[tiab] OR "lean mass"[tiab] OR "visceral fat"[tiab] OR "fat mass"[tiab]) AND humans[mh] (91 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: tirzepatide[tiab] AND (blood pressure[tiab] OR cholesterol[tiab] OR lipid*[tiab]) AND (randomized controlled trial[pt] OR meta-analysis[pt]) (58 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: tirzepatide[tiab] AND (SURPASS-CVOT OR "cardiovascular events" ) AND "dulaglutide"[tiab] AND randomized controlled trial[pt] (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17PubMed search: tirzepatide[tiab] AND (depression[tiab] OR anxiety[tiab] OR "mental health"[tiab] OR ADHD[tiab] OR "binge eating"[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18PubMed search: tirzepatide[tiab] AND (menopaus*[tiab] OR PCOS[tiab] OR "polycystic"[tiab] OR testosterone[tiab] OR hypogonadism[tiab]) (55 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 19PubMed search: selank[tiab] (68 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 20PubMed search: selank[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 21PubMed search: semax[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 22PubMed search: selank[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 23Official web pageOfficial web page · web page
- 24Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome.Medical hypotheses · 2007PMID 16996699Accessed 2 Oct 2026
Found an error? Report a correction.